Dulaglutide

7 trials 2 recruiting AGastroenterology

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

4 Completed trials

6 Sponsors

14 Countries

Phase III

Phase II

Phase IV

Phase III: 3 Phase II: 1 Phase IV: 3

Indications tested

Multiple sclerosis 1 Type 2 diabetes mellitus 1

Sponsors using this IMP

Bellvitge University Hospital 2 Eli Lilly & Co. 2 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL 2 Comenius University Bratislava 1 Eli Lilly Cork Limited 1 Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA 1

All trials

7 total

Effects of GLP-1 analogue in multiple sclerosis Pending

2024-519235-42-00 Phase II 1 country Comenius University Bratislava
A Study of Tirzepatide Compared with Intensified Conventional Care in Adult Participants with Type 2 Diabetes (SURPASS-EARLY) Recruiting

2022-501073-40-00 Phase IV 5 countries Eli Lilly & Co.
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: randomized clinical trial. Study 1: Immediate Kidne… Recruiting

2023-506437-29-00 Phase III 1 country Bellvitge University Hospital; Fundacio Institut D'Investigacio Biomedica De Bel…
Clinical trial to evaluate whether personalized treatment based on genetics improves type 2 diabetes control Ended

2025-520686-46-00 Phase IV 1 country Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospita…
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial. Study 2… Ended

2023-506436-33-00 Phase III 1 country Bellvitge University Hospital; Fundacio Institut D'Investigacio Biomedica De Bel…
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended

2022-500101-41-00 Phase IV 4 countries Eli Lilly Cork Limited
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Phase III 14 countries Eli Lilly & Co.

Showing 1–7 of 7 trials

← All drugs A–Z